More than 50 insurers have pledged to streamline and simplify the prior authorization process through six new commitments.

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...

SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.

Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a ...

Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. | Nektar Therapeutics is enjoying the sweet taste of clinical trial success after ...

How TIME and Statista Determined the World's Most Sustainable Companies of 2025 In the fight against climate change, ...

Nektar Therapeutics said on Tuesday its experimental eczema drug had met the main goal of a mid-stage study, sending its shares up by more than 140% in premarket trading.In the 393-patient trial, drug ...